Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × osimertinib × CNS × Clear all

Phase

Phase 2 9 Phase 1 3 Phase NA 1 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 27 Other solid neoplasm 2 Head & Neck 2 Gastrointestinal 2 Breast 2 Gynecologic 1 Genitourinary 1 Dermatologic 1 CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1

Interventions

Temozolomide 94 Radiotherapy 43 Bevacizumab 29 Carboplatin 22 Irinotecan 18 Radiosurgery 16 pembrolizumab 15 Radiation 14 Nivolumab 14 Magnetic Resonance Spectroscopy 9 Cyclophosphamide 9 Trastuzumab 8 Surgical Procedures, Operative 7 Radiotherapy, Intensity-Modulated 7 Pemetrexed 7 Paclitaxel 7 Interleukin-2 7 Filgrastim 7 Erlotinib Hydrochloride 7 Carmustine 7 fludarabine 6 Specimen Handling 6 Ipilimumab 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 Everolimus 6 Capecitabine 6 aldesleukin 5 Vorinostat 5 Radiotherapy, Conformal 5 Melphalan 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07206498 2025-11-28

WAYWIN103

Wayshine Biopharm, Inc.

Phase 1/2 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡